Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Altamura

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Pageof 14